Description

BSE notifies listing and trading permission for 23,06,372 new equity shares of Eris Lifesciences Limited issued on preferential basis to non-promoters, effective March 10, 2026.

Summary

BSE has notified trading members that 23,06,372 new equity shares of Eris Lifesciences Limited (Scrip Code: 540596, ISIN: INE406M01024) have been listed and are permitted to trade on the Exchange with effect from Tuesday, March 10, 2026. The shares were issued on a preferential basis to non-promoters at an issue price of Rs. 1,835.35 per share.

Key Points

  • 23,06,372 equity shares of Rs. 1/- each issued at a premium of Rs. 1,834.35/- per share to non-promoters on a preferential basis
  • Issue price: Rs. 1,835.35 per share
  • Shares rank pari-passu with existing equity shares of the company
  • Distinctive numbers: 137956022 to 140262393
  • Date of allotment: January 16, 2026
  • ISIN: INE406M01024
  • All 23,06,372 shares are subject to lock-in until February 14, 2029

Regulatory Changes

No regulatory changes introduced. This is a standard listing notification for newly allotted securities pursuant to a preferential allotment.

Compliance Requirements

  • Trading members are informed to note the listing and trading commencement of these new securities
  • The lock-in restriction on all 23,06,372 shares must be observed until February 14, 2029; these shares cannot be traded until the lock-in period expires

Important Dates

  • Date of Allotment: January 16, 2026
  • Trading Commencement: March 10, 2026
  • Lock-in Expiry: February 14, 2029

Impact Assessment

The listing increases the total equity share capital of Eris Lifesciences Limited. Since all newly listed shares are locked in until February 14, 2029, there is no immediate increase in the freely tradable float. The preferential allotment to non-promoters at Rs. 1,835.35 per share reflects the company’s capital-raising activity. Market impact is expected to be minimal in the near term given the lock-in constraint.

Impact Justification

Routine listing of preferentially allotted shares; relevant to existing and prospective shareholders of Eris Lifesciences but does not alter market-wide rules or regulations.